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Background. Cerebrovascular reactivity (CVR) is often impaired in the early phase after aneurysmal subarachnoid hemorrhage.
There is, however, little knowledge about the time course of CVR in patients treated for unruptured intracranial aneurysms (UIA).
Methods. CVR, assessed by transcranial Doppler and acetazolamide test, was examined within the first postoperative week after
treatment for UIA and reexamined one year later. Results. Of 37 patients initially assessed, 34 were reexamined after one year.
Bilaterally, baseline and acetazolamide-induced blood flow velocities were higher in the postoperative week compared with one
year later (𝑝 < 0.001). CVR on the ipsilateral side of treatment was lower in the initial examination compared with follow-up
(58.9% versus 66.1%, 𝑝 = 0.04).There was no difference in CVR over time on the contralateral side (63.4% versus 65.0%, 𝑝 = 0.65).
When mean values of right and left sides were considered there was no difference in CVR between exams. Larger aneurysm size
was associated with increased change in CVR (𝑝 = 0.04), and treatment with clipping was associated with 13.8%-point increased
change in CVR compared with coiling (𝑝 = 0.03). Conclusion. Patients with UIA may have a temporary reduction in CVR on the
ipsilateral side after aneurysm treatment.The change in CVR appears more pronounced for larger-sized aneurysms and in patients
treated with clipping. We recommend that ipsilateral and contralateral CVR should be assessed separately, as mean values can
conceal side-differences.
1. Introduction
Constriction and dilation of cerebral arterioles regulate cere-
bral blood flow. Cerebrovascular reactivity (CVR) reflects
this regulating capacity and is a marker of cerebrovascular
integrity. Impaired CVR is associated with increased risk
of cerebro- and cardiovascular disease and death [1]. The
temporal development of CVR has been studied in healthy
subjects and in patients with cerebrovascular disease. In
healthy persons, CVR is stable over time [2]. In the early
phase after aneurysmal subarachnoid hemorrhage (aSAH),
CVR is often impaired [3–8], especially in patients with
massive hemorrhage, poor neurological status at admission,
and vasospasm [9–15]. It has been suggested that transient
reduction of CVR after aSAH may be associated with devel-
opment of delayed cerebral ischemia and poor outcome [9,
16, 17]. There is, however, little knowledge regarding the
time course of CVR in patients with unruptured intracranial
aneurysms (UIA). It is unknownwhether, andhow, aneurysm
treatment affects CVR. Information on the time course of
CVR in patients treated for UIA may help in differentiating
between potential effects of aneurysm treatment and the
impact of an aneurysm bleeding.
The main objective of this study was to evaluate the time
course of CVR in patients treated for an UIA by comparing
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CVR within the first week after aneurysm treatment with
CVR one year later. We further wanted to assess whether
other factors like age, sex, smoking, hypertension, body mass
index, aneurysm size, treatment side, or treatment modality
were associated with the stability of CVR over time.
2. Methods
2.1. Participants and Time Scheme. In a previous study, we
analyzed early postoperative CVR data from patients treated
for UIA in the Department of Neurosurgery, Haukeland
University Hospital, between February 2011 and May 2013
[18]. The patients were treated with either endovascular
coiling or surgical clipping, and they were examined within
the first week after aneurysm treatment. In the present
study, CVR was reevaluated in the same patients one year
after aneurysm treatment. Exclusion criteria were iden-
tical to those used in the previous study: former treat-
ment of intracranial aneurysms; nonsaccular aneurysms;
giant aneurysms treated with proximal artery occlusion;
carotid stenosis (>50%) or occlusion; lack of transtem-
poral bone window in transcranial Doppler examination;
and contraindications to acetazolamide (e.g., sulfonamide
allergy, adrenal or pituitary insufficiency, and kidney or liver
failure).
Demographics, aneurysm location, and treatment were
recorded, as well as body mass index, smoking status, and
hypertension (previously diagnosed and treated or systolic
pressure > 140mmHg and/or diastolic pressure > 90mmHg
persistently observed during admission). Aneurysm size
was measured using the following parameters: maximum
diameter of the dome, independent of angles and directions
(maximum diameter, Dmax), maximum diameter of the
dome, perpendicular to the aneurysm height (width, 𝑊),
maximum height from dome tip perpendicular to aneurysm
neck (height, 𝐻), and diameter of the aneurysm neck (neck,
𝑁). Aspect ratio (𝐻/𝑁) and bottleneck ratio (𝑊/𝑁) were
calculated [19, 20].
The study was conducted in accordance with the Declara-
tion of Helsinki (2013) of the World Medical Association and
was approved by the local ethics committee. All patients gave
written informed consent.
2.2. Cerebrovascular Reactivity. CVR testing was performed
using transcranial Doppler (TCD) monitoring of blood flow
velocities in the middle cerebral arteries (MCA) before,
during, and after intravenous injection of acetazolamide
(AZ). The method has previously been described in detail
[18]. Except for an additional manufacturer of AZ, the
method of CVR testing was identical to the initial study [18].
The AZ manufacturers used in this study were Goldshield
Ltd., Croydon, Surrey, UK; Sanofi Aventis, Paris, France; and
Mercury Pharmaceuticals Ltd., Croydon, Surrey, UK. The
AZ dose was 1000mg for patients weighing < 80 kg, and
15mg/kg for patients weighing ≥ 80 kg. The maximum dose
was 1500mg. All examinations in the initial and follow-up
study were performed by the same sonographer (MLB).
Cerebrovascular reactivity was defined as the maximum
percentage change in mean blood flow velocity (MFV)
after administration of AZ: CVR (%) = [(MFVAZ −
MFVBASELINE)/MFVBASELINE] × 100, where CVR is cere-
brovascular reactivity, MFVBASELINE is baseline mean blood
flow velocity (before AZ), and MFVAZ is maximum mean
blood flow velocity after AZ.
2.3. Statistical Analysis. Two measures of central tendency
and dispersion were used: mean and standard deviation (SD)
for variables that were symmetric around the mean, and
median and interquartile range (IQR) for those that were
nonsymmetric. In cases where patients underwent treatment
for multiple aneurysms during the same procedure, averaged
aneurysm size was used in the analyses. The relationships
between blood flow velocities and CVR at the time of
initial examination and one year later were studied using
paired 𝑡-tests. Paired 𝑡-test was also used to assess possible
differences in velocities and CVR related to side (right/left
and ipsilateral/contralateral to the aneurysm treatment).
Regarding treatment modality (clipping or coiling), two-
sample 𝑡-tests were used. To simplify analyses, patients with
midline aneurysms were allocated to the side chosen for
endovascular or surgical approach. As in the previous study
[18],meanCVRof the two sides (right and left)was calculated
for all individuals. If the measurement on one side was
missing, the mean CVR was set to the nonmissing value.
Simple linear regressions, stratified on treatment modality,
were conducted on mean CVR at follow-up versus mean
CVR at first examination. Also, difference in mean CVR
between first exam and follow-up was the outcome in a
multiple regression and a set of simple linear regressions.
Covariates were age, sex, hypertension, smoking, body mass
index, weight difference from initial exam to follow-up,
treatment modality, maximum aneurysm diameter (Dmax),
mean CVR at the time of initial examination, and difference
in mean AZ dose per kg from initial exam to follow-
up. Lastly, maximum aneurysm diameter was included as
covariate in a simple linear and multiple regression with
CVR at the time of the initial examination as outcome, in
addition to the covariates tested in a previous report (age,
sex, hypertension, smoking, body mass index, and treatment
modality) [18]. The regression analyses were repeated with
ipsilateral CVR as outcome variable instead of mean CVR,
and with stratification for age, sex, and treatment modality.
All statistical analyses were performed with R version
3.4.3 [21].
3. Results
3.1. Patients, Aneurysm, and Treatment. Of 37 patients exam-
ined in the initial study, two patients chose to abstain from
the follow-up test due to side effects of AZ at the initial
examination, and one patient did not meet for follow-up
due to long travel to the hospital. This left us with a study
population of 34 patients.
Table 1 shows patient characteristics. Weight difference is
the difference in body weight from the first examination to
follow-up. All other variables listed in the table were recorded
at the time of aneurysm treatment.Mean agewas 49.0 (SD9.6,
range 27–65) years. In 20 of the 34 patients (58.8%) the body
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Table 1: Patients characteristics.
(𝑛 = 34)
Age, yearsa 49.0 (9.6)
Height, cma 169.2 (8.6)
Weight, kga 76.1 (15.5)
BMI, kg/m2a 26.5 (4.8)







amean (SD); bn (%); BMI: body mass index; SD: standard deviation.
weight was different at the time of follow-up compared with
the first examination (range 10 kg reduction–13 kg increase).
In 11 patients (32.4%) the weight difference was >2 kg. Table 2
shows aneurysm and treatment characteristics.
3.2. Cerebrovascular Reactivity. In total, 56 bilateral and 12
unilateral examinations were performed in the 34 patients.
Unilateral examinations were more common in the initial
exams (23.5%) compared with follow-up (11.8%), presumably
because postoperative intracranial air can cause insufficient
insonation. Median time between treatment and initial exam
was 51.0 (IQR 39.5) hours. Median time between treatment
and follow-up exam was 376.5 (IQR 31.8) days. Median time
between initial examination and follow-up was 374.5 (IQR
29.3) days.
Of 68 examinations, 42 (61.8%) were performed using
1000mg AZ. The remaining 26 examinations (38.2%) were
donewith 15mgAZper kg because of high bodyweight.Mean
bodyweightwas 76.1 (SD 15.5, range 40 to 110) kg at the time of
the first examination and 76.6 (SD 17.2, range 40 to 118) kg at
follow-up. Mean AZ dose was 15.1 (SD 2.3) mg/kg in the first
examination and 15.1 (SD 2.4) mg/kg at follow-up. There was
no correlation between AZ dose per kg and CVR (Pearson’s
𝑅 = 0.08, 𝑝 = 0.66 in the first examination, and 𝑅 = −0.11,
𝑝 = 0.52 at follow-up).
Table 3 shows blood flow velocities and CVR results. In
the initial examination MFV in the middle cerebral arteries
was 58.6 cm/s before stimulation with AZ and 94.3 cm/s after,
giving amean CVR of 62.7%. Follow-up testing showedMFV
51.4 cm/s before AZ, 84.4 cm/s after, andmeanCVRof 65.6%.
Bilaterally, baseline and AZ-induced blood flow velocities
were higher in the postoperative week compared with 1 year
after aneurysm treatment (𝑝 ≤ 0.009 in all situations).
When assessing mean values of the right and left sides, no
difference between CVR at first examination and follow-up
was found (𝑝 = 0.31). When assessing CVR according to
treatment laterality, there was no difference over time on the
contralateral side (65.0% at follow-up versus 63.4% at the
initial examination, 𝑝 = 0.65). However, on the ipsilateral
side of aneurysm treatment there was an apparent change
in CVR over time. Ipsilateral CVR was 58.9% (SD 19.3) in
the initial examination versus 66.1% (SD 18.5) at follow-up
(𝑝 = 0.04), corresponding to an absolute increase of 7.2%
and relative increase of 12%. Subgroup analyses for treatment
modalities had lower sample sizes, and the significance
disappeared (𝑝 = 0.16). CVR change on the ipsilateral side
seemed larger in patients treatedwith clipping comparedwith
patients treated with coiling (absolute increase 10.5 versus
4.7%, and relative increase 17 versus 8%), yet the number of
patients in each subgroup is low (𝑛 = 12 for clipping and
𝑛 = 22 for coiling) and results are inconclusive (𝑝 = 0.42).
The same trend was found for mean CVR values of the right
and left side, with an absolute and relative increase of 8.7%
and 13% in patients treatedwith clipping versus 0.2% absolute
reduction and 0% relative change in patients treated with
coiling (𝑝 = 0.18). The tendency of larger CVR difference
between exams was present for all patients treated with
aneurysm clipping, regardless of whether temporal clipping
of a parent artery was performed or not. However, despite
similar values for CVR difference between exams, patients
treated with temporal clipping appeared to have higher
CVR values compared with patients treated with “standard”
clipping (without the need for temporary clipping), at both
the initial exam and follow-up. Due to few observations,
statistical power is however insufficient to evaluate potential
differences within the clipping subgroup.
Table 4 shows the results of the regression analyses
regarding the relationship between difference in mean CVR
from the first examination to follow-up and several different
variables. In the simple analysis, maximum aneurysm diam-
eter and CVR in the first examination were associated with a
change in CVR. An 1mm increase in the maximum diameter
of the aneurysm dome was associated with an increase in
CVR difference by 3.2 and 2.5 percentage points in the simple
and multiple regressions, respectively (𝑝 = 0.005 and 𝑝 =
0.04). For every percentage point increase in CVR in the first
examination, the change in CVR from initial exam to follow-
up was reduced with 0.3 percentage points (𝑝 = 0.05). The
association was stronger in the multiple model, where the
reduction in CVR change was 0.5 percentage points for every
percentage point increase in CVR in the first examination
(𝑝 = 0.01). In the multiple analyses age and treatment
modality were also associated with change in CVR. For age,
the change in CVR increased with 0.8 percentage points
per year (𝑝 = 0.03). For treatment modality, the multiple
model showed that patients treated with clipping had 13.8
percentage points increased change in CVR compared with
patients treated with coiling (𝑝 = 0.03). There were no
associations between change in CVR and sex, body mass
index, body weight difference between exams, hypertension,
and smoking. There were no major changes in the results
when regression analyses were repeated after stratification for
sex, age (≤50 years versus >50 years), and treatment modality
(coiling versus clipping).
Regression analyses were also repeated with ipsilateral
CVR as outcome variable instead ofmean CVR. Patients with
missing CVR values on the ipsilateral side, at the time of
either the first exam or follow-up, were excluded.This applied
to 7 of 34 (20.6%) patients: 2 of 22 (9.1%) patients treated
with coiling and 5 of 12 (41.7%) patients treated with clipping.
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Table 2: Aneurysm and treatment characteristics.
𝑛 = 34
Multiple aneurysms, 𝑛 (%) 12 (35.3)
Treatment modality, 𝑛 (%)
Coil 22 (64.7)
Clipa 12 (35.3)
Treatment side, 𝑛 (%)b
Left 18 (52.9)
Right 16 (47.1)
Location of treated aneurysms, 𝑛 (%)
MCA 14 (41.2)
ICA, incl. ophthalmic artery and PCOM 10 (29.4)
ACOM, anterior complex, and pericallosal artery 7 (20.6)
Basilar top, cerebelli superior, PICA, VB, and distal posterior 3 (8.8)
Size of treated aneurysms, mean (SD)c
Maximum diameter (𝐷max), mm 6.3 (2.4)
Height (𝐻), mm 6.4 (2.8)
Neck (𝑁), mm 4.1 (1.8)
Width (𝑊), mm 5.4 (2.2)
Aspect ratio (𝐻/𝑁) 1.6 (0.5)
Bottleneck ratio (𝑊/𝑁) 1.4 (0.5)
aIn four of twelve patients temporal clipping of a parent artery was performed; bone patient treated with combined clipping of an ACOM aneurysm and a
right MCA aneurysm in one procedure was allocated to the right side. Eight patients with midline aneurysms (ACOM and basilar top) were allocated to the
chosen side of approach; cthe majority of patients received treatment for a single aneurysm. For the 4 of 34 patients (11.8%) that underwent treatment for
two aneurysms during the same procedure, aneurysm size was averaged; ACOM: anterior communicating artery; ICA: internal carotid artery; MCA: middle
cerebral artery; PCOM: posterior communicating artery; PICA: posterior inferior cerebellar artery; VB: vertebrobasilar artery; maximum diameter (𝐷max):
maximum diameter of the dome (independent of angles and directions); height (𝐻): maximum height from dome tip perpendicular to aneurysm neck; neck
(𝑁): diameter of the aneurysm neck; width (𝑊): maximum diameter of the dome, perpendicular to the aneurysm height (𝐻).
The lower sample size in the analyses with ipsilateral CVR
as outcome yielded more uncertainty. Apart from higher 𝑝
values, findings were primarily consistent with the results
of the original regressions using mean CVR as outcome.
Maximum aneurysm diameter and CVR at first exam were
still associated with change in ipsilateral CVR between exams
in the simple analysis (𝑝 = 0.05), whereas the multiple
analysis provided weaker evidence for such associations (𝑝 =
0.22 for aneurysm diameter and 𝑝 = 0.10 for first CVR).
The positive association between change in CVR and age and
clipping found in the regression with mean CVR was less
obvious in the regression with ipsilateral CVR. The estimate
for age was 0.7 (𝑝 = 0.10) versus 0.8 (𝑝 = 0.03) in the
regression with mean values. The estimate for clipping was
9.8 (𝑝 = 0.19) in the regression with ipsilateral values versus
13.8 (𝑝 = 0.03) in the regression with mean values.
Finally, regression analyses were performed to assess if
larger aneurysm diameter was correlated with lower initial
CVR. When only results from the initial exam were included
in the statistical analyses, fewer observations yielded high 𝑝
values.Maximumaneurysmdiameter had an estimate of−0.6
in the simple analysis (𝑝 = 0.61) and −1.7 in the multiple
analysis (𝑝 = 0.15). Few observations hamper the assessment
of a possible association between larger aneurysm size and
reduced CVR in the first week after aneurysm treatment.
Figure 1 shows a scatter plot of mean CVR at first exam
and follow-up. The regression lines for the two treatment
modalities are almost parallel, with the line for patients
treated with clipping shifting up about 8 to 15 percentage
points. This is in accordance with Table 4.
Figure 2 shows box plots comparing change in mean
CVR from first exam to follow-up in patients treated with
coiling and clipping. Although there was little evidence for
difference in mean CVR change in patients treated with
coiling compared with clipping (𝑝 = 0.14), Figure 2 hints
that patients treated with clipping had a greater difference
between the initial examination and follow-up. Still, the
evidence is inconclusive.
Diamox Goldshield Ltd. was used in 44 CVR tests
(64.7%), Sanofi Aventis in 20 tests (29.4%), and Mercury
Pharmaceuticals Ltd. in 4 tests (5.9%). There did not seem
to be any important differences in CVR between the three
manufacturers (Mercury versus Goldshield: 𝑝 = 0.07;
Mercury versus Sanofi Aventis: 𝑝 = 0.84; Goldshield versus
Sanofi Aventis: 𝑝 = 0.46).
4. Discussion
4.1. Main Findings. In this study, we found a lower CVR
on the ipsilateral side of aneurysm treatment in the post-
operative week compared with one-year follow-up. There
was no evidence of any difference in CVR over time when
mean values of the right and left sides were assessed. Larger
aneurysm size is associated with increased change in CVR.
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Table 3: Blood flow velocities and cerebrovascular reactivity at baseline and follow-up.
First exam Follow-up Absolute
difference
Relative
difference 𝑝mean (SD) mean (SD)
MFVBASELINE (cm/s)
Ipsilateral 59.8 (13.8) 51.2 (13.3) −8.6 0.86 <0.001
Contralateral 57.7 (14.7) 52.0 (12.1) −5.7 0.90 0.003
Mean 58.6 (13.2) 51.4 (11.7) −7.2 0.88 <0.001
MFVAZ (cm/s)
Ipsilateral 93.6 (18.0) 84.4 (20.2) −9.2 0.90 0.001
Contralateral 93.4 (23.3) 85.0 (20.1) −8.4 0.91 0.009
Mean 94.3 (20.0) 84.4 (18.5) −9.9 0.90 <0.001
ΔMFV (cm/s)
Ipsilateral 33.8 (9.2) 33.1 (9.8) −0.7 0.98 0.43
Contralateral 35.7 (11.2) 33.0 (11.8) −2.7 0.93 0.15
Mean 35.7 (10.2) 33.1 (9.9) −2.7 0.93 0.09
CVR (%)
Ipsilateral 58.9 (19.3) 66.1 (18.5) 7.2 1.12 0.04
Contralateral 63.4 (17.5) 65.0 (23.6) 1.7 1.03 0.65




CVR: cerebrovascular reactivity;MFVBASELINE: baseline mean blood flow velocity (before acetazolamide);MFVAZ: maximummean blood flow velocity after
acetazolamide; ΔMFV: absolute change in mean flow velocity after acetazolamide; MV: missing value; 𝑝: 𝑝 value from paired 𝑡-test (follow-up–first); SD:
standard deviation. Note that if one side had a missing value, the mean is just the remaining value. This is why the mean is not simply the mean of ipsilateral
and contralateral values. Patients with MV were excluded from the paired 𝑡-test. The sample size was therefore reduced in the analyses of ipsilateral and
contralateral values (ipsilateral 𝑛 = 27, contralateral 𝑛 = 33, mean 𝑛 = 34).
Table 4: Regression results: difference in mean CVR between exams versus a number of variables.
Simple Multiple
Estimate 𝑝 Estimate 𝑝
Age, years 0.1 0.68 0.8 0.03
Female −4.9 0.42 −4.5 0.46
BMI, kg/m2 −0.2 0.78 −0.1 0.84
Weight difference, kg 0.3 0.63 0.3 0.81
Hypertension 1.7 0.78 3.3 0.58
Smoking
Current ref - ref -
Previous −2.8 0.67 −2.8 0.62
Never −5.2 0.59 −0.7 0.94
Treatment modality
Coil ref - ref -
Clip 9.0 0.14 13.8 0.03
Maximum aneurysm diameter (Dmax) 3.2 0.005 2.5 0.04
Mean CVR at first exam, % −0.3 0.04 −0.5 0.01
Difference in AZ dose per kg −2.4 0.49 −1.9 0.81
AZ: acetazolamide; BMI: body mass index; CVR: cerebrovascular reactivity; Dmax: maximum diameter of the aneurysm dome (independent of angles and
directions); ref: reference.
In addition, results suggest that the difference in CVR may
be greater in patients treated with clipping compared with
coiling, but evidence is inconclusive.
In a previous study, where CVR was examined in the first
week after aneurysm treatment, we did not find any difference
when comparing treated and untreated sides (59.4% versus
63.0%, 𝑝 = 0.16) [18]. We concluded that CVR in patients
with UIA did not differ from normal values reported in
healthy subjects and that findings did not indicate a system-
ically impaired vascular system in patients with UIA. New
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Figure 1: Scatter plot of mean cerebrovascular reactivity (CVR)
at the time of initial examination and follow-up, together with
regression lines. Results for patients treated with coiling are marked
with red triangles, and results for patients treated with clipping are

































Figure 2: Box plots comparing change in mean cerebrovascular
reactivity (CVR) from the first examination to follow-up in patients
treated with coiling and clipping. Boxes extend from the 25th to the
75th percentile. Horizontal bars represent the median, and whiskers
extend to the most extreme point that is less than 1.5 times the
interquartile range from the box. Mean values are marked with
crosses, and a single outlier is depicted as a circle.
information based on results from follow-up testing one year
later now indicates that theremay be a side difference in CVR
after aneurysm treatment after all. Ipsilateral CVR was 58.9%
after treatment versus 66.1% one year later, and contralateral
CVR was 63.4% after treatment versus 65.0% one year later.
The postoperative CVR of 58.9% seems to stand out as lower
than the other CVR values, indicating a temporary reduction
in CVR on the treated side. Even though we could not rule
out the fact that the trend with lower CVR on the ipsilateral
side was due to chance when only postoperative results were
assessed (𝑝 = 0.16) the difference was more pronounced
when follow-up resultswere included (difference in ipsilateral
CVR over time, 𝑝 = 0.04). Still, the sample size is limited and
results must be interpreted with caution.
Furthermore, this study showed higher baseline and AZ-
induced blood flow velocities in the postoperative week
compared with one year after aneurysm treatment. The
increased velocities can be explained by postoperative hyper-
emia. Transient hyperemia is common after craniotomy [22].
However, hyperemia has previously only been found in the
first postoperative hour [22], and themedian time for the first
CVR testing in our studywas 51.0 (IQR 39.5) hours after treat-
ment. To our knowledge, there have been no reports about
transient hyperemia after endovascular aneurysm treatment.
Alternatively, posttreatment spasm could be the cause of
elevated blood flow velocities at the initial exam. Moreover,
comparison of absolute blood flow velocities is problematic
as the probe positioning and insonation angle probably were
different at the time of the initial and follow-up exam. Still,
there is no reason why altered insonation angle and probe
positioning should only cause increased velocities. In theory,
changes in technical insonation aspects could just as well
cause a reduction of measured velocities.
Our finding of reduced CVR on the ipsilateral side
after aneurysm treatment may be related to postoperative
hyperemia. It is possible that a transient hyperemia in
response to aneurysm clipping or coiling affects the arteriolar
vasodilating capacity and thus influences CVR. Baseline
velocities (MFVBASELINE) were higher at first exam compared
with one-year follow-up (59.8 cm/s versus 51.2 cm/s, 𝑝 <
0.001), whereas the absolute change in velocity (ΔMFV) was
the same at the two examination times (33.8 cm/s versus
33.1 cm/s, 𝑝 = 0.43). Since CVR is defined as percentage
change in velocity after AZ compared with baseline, the same
ΔMFV yields lower CVR values when baseline velocities are
increased (unchanged numerator and higher denominator
of the fraction). An alternative explanation for decreased
CVR after aneurysm treatment may be that harboring an
aneurysm in itself impairs CVR. This effect may still be
present in the first postoperative days, while vasodilating
capacity can be restored after aneurysm treatment and CVR
normalized one-year later. Since TCD and AZ testing were
not performed prior to aneurysm treatment it is difficult to
say if the reduction in CVR is caused by the aneurysm itself
or by aneurysm treatment.
4.2. Time Course of CVR in Healthy Subjects. Schwertfeger
et al. (2006) assessed the time course of CVR in healthy
subjects [2]. TCD and AZ were used to investigate CVR in
33 healthy subjects at baseline and after 1 to 3 years (mean
21.6 months). They performed unilateral testing and found
no changes in CVR over time. Like in our study, they did
not find any association between sex and smoking and CVR
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change. Unlike their findings, we found a positive association
between age and change in CVR from first examination to
follow-up (𝑝 = 0.03 in the multiple regression model). The
possible influence by age on CVR is unclear, and studies in
healthy subjects have shown varying effects [23–30].
4.3. Time Course of CVR in Patients with Intracranial
Aneurysms. Several studies have assessed the time course of
CVR in patients with ruptured intracranial aneurysms. CVR
is often impaired in the early phase after aSAH [3–6],
especially in patients with massive hemorrhage, poor neu-
rological status at admission, and vasospasm [9–15]. There
is a possible association between progressive impairment
in CVR in the early phase after aSAH and subsequent
development of delayed cerebral ischemia [9, 16]. Transient
reduction of CVR may also be associated with poor outcome
[17]. Follow-up studies months and years after aSAH have
shown normalization of CVR, regardless of the severity of
hemorrhage and presence of vasospasm in the acute phase
[31–33]. In contrast to the numerous studies on CVR in
patients with aSAH there are few studies addressing CVR in
patients with UIA. To our knowledge only one study has used
AZ test and TCD to assess CVR in this patient group [18],
and six reports have used CO2 as vasoactive stimuli [3, 4, 7,
14, 15, 33]. In these studies, CVR testing was performed either
at a single time-point after aneurysm treatment [18, 33] or at
multiple time-points within 24 hours in close relation to the
time of aneurysm surgery [3, 4, 7, 14, 15]. To our knowledge,
this is the first study to investigate within-subject differences
over time in patients treated for UIA. We found evidence in
favor of a transient reduction of CVR on the ipsilateral side
of aneurysm treatment, and recommend separate assessment
of ipsilateral and contralateral CVR as mean values of right
and left sides can conceal side-differences. Our finding of
possible transient reduction of CVR also after treatment for
unruptured aneurysms provides valuable insight and may
enable better interpretation of CVR results after aneurysm
treatment.
Studies with measurement of CVR at a single time-point
have not shown any association between CVR and aneurysm
treatment modality [18, 31], whereas in this follow-up study a
possible association between treatment modality and change
in CVR was found. Patients treated with aneurysm clipping
appeared to have a larger difference in CVR between exams.
This tendency was present for all patients treated with
aneurysm clipping, regardless of whether temporal clipping
of a parent artery was performed or not. Still, the number
of patients in the subgroups for treatment modality is low.
In particular, the number of observations in patients treated
with clipping is reduced due to missing values, presumably
related to postoperatively intracranial air. Results should thus
be interpreted with caution.
4.4. Technical Considerations. Blood flow velocities demon-
strate diurnal variations [34].The follow-up examination was
not performed at the identical time of day as the initial
CVR test, but the time differences between exams were small
(median 2.25 hours, IQR 2.56 hours) and we consider their
influence as negligible. Mean AZ dose was the same in the
first examination and follow-up (mean 15.1mg/kg, SD 2.3
and 2.4mg/kg, respectively). A third of the patients had
a weight difference of >2 kg from first exam to follow-up.
Nonetheless, the weight difference was small (mean 0.4 kg,
SD 4.7 kg) and there was no association between weight
difference and change in CVR (𝑝 = 0.93). We used different
brands of AZ, but there was no differences in CVR between
the three manufacturers. As expected, insufficient insonation
due to postoperative intracranial air was more common on
the ipsilateral side of aneurysm clipping compared with the
contralateral side, or compared with patients treated with
coiling.
4.5. Strengths and Limitations. To our knowledge, this is the
first study to investigate within-subject differences in CVR
over time in patients treated for UIA.The sample size is in the
upper range compared with CVR studies in healthy subjects
[2, 35–46]. The method of testing was identical at initial
examination and follow-up. We used the same sonographer
(MLB) in all examinations to reduce operator variability, as
the intrarater reproducibility for TCD examinations has been
found superior to interrater [47, 48].
The AZ dose should ideally have been bodyweight-based
in all patients in the study, not only in patients weighing
≥80 kg. Still, the recommended AZ dose of 13 to 18mg/kg
[39, 49] was achieved for the vast majority of patients (91.2%).
Bloodflowvelocities are affected by physiological factors such
as hematocrit, arterial CO2 tension, heart rate, and mean
arterial pressure [50], and hyperventilation can theoretically
counteract the vasodilatory effect of AZ.We did not routinely
monitor these parameters in our study.
Even though the sample size is rather large comparedwith
other CVR studies, the limited number of patients makes
it difficult to draw definite conclusions regarding regression
results and subgroup effects, especially for treatment modal-
ity. The regression analyses based on ipsilateral CVR were
hampered by missing values in several patients, especially in
patients treated with clipping. Subgroup analysis based on
laterality and treatment modality should be considered when
planning the sample size of future studies.
To best assess the effect of aneurysm treatment on CVR
it would have been preferable to examine patients before
and after the procedure. Patients were not examined before
aneurysm treatment in our study, partly because this study
was part of a larger study where the set-up was designed
for comparison of CVR in patients treated for ruptured and
unruptured aneurysms, and partly because we wanted to
avoid test-induced aneurysm rupture, a highly unlikely yet
serious complication.
5. Conclusions
This study implies that patients with UIA may have a
temporary reduction in CVR on the ipsilateral side after
aneurysm treatment. The change in CVR is associated with
larger aneurysm size and is possibly more pronounced in
patients treated with clipping. We recommend that results
from ipsilateral and contralateral sides should be assessed
separately as mean values can conceal side-differences in
CVR.
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